Export this record

Export record to excel

File type to download

Beta version

Select record 2

ArticlesPeer ReviewedFull Text

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3...

Author / Creator:Bührer, Emanuel, MD ; Kicinski, Michal, PhD ; Mandala, Mario, MD ; Pe, Madeline, PhD ; Long, Georgina V, Prof ; Atkinson, Victoria, MD ; Blank, Christian U, MD ; Haydon, Andrew, MD ; Dalle, Stéphane, Prof ; Khattak, Adnan, MD ; Carlino, Matteo S, BMedSc ; Meshcheryakov, Andrey, Prof ; Sandhu, Shahneen, Prof ; Puig, Susana, Prof ; Schadendorf, Dirk, Prof ; Jamal, Rahima, MD ; Rutkowski, Piotr, Prof ; van den Eertwegh, Alfonsus J M, Prof ; Coens, Corneel, MSc ; Grebennik, Dmitri, MD ; Krepler, Clemens, MD ; Robert, Caroline, Prof ; Eggermont, Alexander M M, Prof

Publisher:England: Elsevier Ltd

Journal title:The lancet oncology, 2024-09, Vol.25 (9), p.1202-1212

View online as a Library member

Export record to excel

Export this record

Export record to excel

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Export this record

Export record to excel

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3...

Refine your search

Search the collection

Export record to excel

Export this record

Export record to excel

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Export this record

Export record to excel

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3...

Refine your search